In­cyte says un­der-the-radar JAK in­hibitor clears a high bar for skin dis­or­der

In­cyte — the com­pa­ny be­hind Jakafi and Olu­mi­ant — wants to put a third JAK in­hibitor on the map.

Pre­sent­ing at the Eu­ro­pean Hidradeni­tis Sup­pu­ra­ti­va Foun­da­tion con­fer­ence, the biotech high­light­ed long-term da­ta from a Phase II tri­al test­ing povorci­tinib as a treat­ment for hidradeni­tis sup­pu­ra­ti­va (HS), a skin con­di­tion char­ac­ter­ized by painful nod­ules and ab­scess­es.

If the re­sults hold up in Phase III, the drug may “es­tab­lish a new high wa­ter mark for ef­fi­ca­cy,” Cowen an­a­lyst Marc Frahm wrote in a note, even as it goes against Ab­b­Vie’s Hu­mi­ra and No­var­tis’ Cosen­tyx.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.